EAM
AVTX icon

Eventide Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Eventide Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-208
Closed -$3.5M – 117
2019
Q1 		$3.5M Buy
+208
New +$3.11M 0.12% 94

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Eventide Asset Management's AVTX Position: Q2 2019 in Review

Eventide Asset Management sold out of Avalo Therapeutics (AVTX) in Q2 2019, closing a stake of 208 shares — an estimated $3.5M sold.

Eventide Asset Management first reported a position in AVTX in Q1 2019 and held it in 1 quarter. The position peaked at $3.5M in Q1 2019. 36 funds tracked by Wall St. Rank hold AVTX as of Q2 2019.

  • Eventide Asset Management reported no remaining Avalo Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Eventide Asset Management sold 208 Avalo Therapeutics shares in Q2 2019, an estimated $3.5M.
  • Eventide Asset Management first reported a position in Avalo Therapeutics in Q1 2019 and held it in 1 quarter.
  • Eventide Asset Management's Avalo Therapeutics position peaked at $3.5M in Q1 2019.
  • 36 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2019.

Based on Eventide Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.